Skip to main content
Top
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Research article

Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system

Authors: Soo Min Jang, Katie E Cardone, Thomas D Nolin, Darius L Mason, Darren W Grabe

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

The purpose of this study was to evaluate the feasibility of utilizing an in-vitro, closed loop hemodialysis system as a method to assess drug clearance. Secondarily, this study tested the influence of variables (blood flow rate, dialysate flow rate, and type of filter) in the hemodialysis procedure on the clearance of vancomycin and gentamicin.

Methods

An in-vitro, closed loop hemodialysis system was constructed. The vancomycin (30 mg/L) and gentamicin (25 mg/L) were added to a simulated blood system (SBS). Four conditions (C1-C4) were tested by defining the filter (Polyflux 170H or F180) and the blood and dialysate flow rates (BFR and DFR). All hemodialysis sessions were 3 hours in length and each condition was completed in duplicate. Dialysate effluent was collected in a 50 gallon polyethylene drum. Samples were collected (in duplicate) from the SBS and the dialysate effluent at baseline and at the end of the hemodialysis session. Samples were analyzed for vancomycin and gentamicin with an ultrahigh performance liquid chromatography/tandem mass spectrometry method.

Results

A total of eight 3-hour hemodialysis sessions were conducted. For all tested conditions (C1-C4), vancomycin was undetectable in the SBS at the end of dialysis. However, total vancomycin recovery in the dialysis effluent was 85±18%, suggesting that up to 15% may have adsorbed to the dialysis filter or tubing. Gentamicin clearance from SBS was >98% in all tested conditions. Average gentamicin recovery in the dialysate effluent was 99±15%.

Conclusion

Both vancomycin and gentamicin were readily removed by high-flux hemodialysis under all conditions studied. No significant differences in drug clearance were observed between conditions used in this in vitro study. The clinical implications of changing these hemodialysis parameters are unknown.
Literature
1.
go back to reference Olyaei AJ, Steffl JL: A quantitative approach to drug dosing in chronic kidney disease. Blood Purif. 2011, 31: 138-145. 10.1159/000321857.CrossRefPubMed Olyaei AJ, Steffl JL: A quantitative approach to drug dosing in chronic kidney disease. Blood Purif. 2011, 31: 138-145. 10.1159/000321857.CrossRefPubMed
2.
go back to reference Verbeeck RK, Musuamba FP: Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009, 65: 757-773. 10.1007/s00228-009-0678-8.CrossRefPubMed Verbeeck RK, Musuamba FP: Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009, 65: 757-773. 10.1007/s00228-009-0678-8.CrossRefPubMed
3.
go back to reference Zoer J, Schrander-van der Meer AM, Van Dorp WT: Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes. Pharm World Sci. 1997, 19: 191-196. 10.1023/A:1008600104232.CrossRefPubMed Zoer J, Schrander-van der Meer AM, Van Dorp WT: Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes. Pharm World Sci. 1997, 19: 191-196. 10.1023/A:1008600104232.CrossRefPubMed
4.
go back to reference Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA: Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy. 1997, 17: 256-262.PubMed Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA: Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy. 1997, 17: 256-262.PubMed
5.
go back to reference Vercaigne LM, Ariano RE, Zacharias JM: Bayesian pharmacokinetics of gentamicin in a haemodialysis population. Clin Pharmacokinet. 2004, 43 (3): 205-210. 10.2165/00003088-200443030-00004.CrossRefPubMed Vercaigne LM, Ariano RE, Zacharias JM: Bayesian pharmacokinetics of gentamicin in a haemodialysis population. Clin Pharmacokinet. 2004, 43 (3): 205-210. 10.2165/00003088-200443030-00004.CrossRefPubMed
6.
go back to reference Stryjewski ME, Szczech LA, Benjamin DK, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG: Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with Methicillin-Susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007, 44: 190-196. 10.1086/510386.CrossRefPubMed Stryjewski ME, Szczech LA, Benjamin DK, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG: Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with Methicillin-Susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007, 44: 190-196. 10.1086/510386.CrossRefPubMed
7.
go back to reference Pai AB, Pai MP: Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm. 2004, 61: 1812-1816.PubMed Pai AB, Pai MP: Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm. 2004, 61: 1812-1816.PubMed
8.
go back to reference DeSoi CA, Sahm DF, Umans JG: Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis. 1992, 20: 354-360. 10.1016/S0272-6386(12)70298-6.CrossRefPubMed DeSoi CA, Sahm DF, Umans JG: Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis. 1992, 20: 354-360. 10.1016/S0272-6386(12)70298-6.CrossRefPubMed
9.
go back to reference Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA: Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol. 1998, 50: 51-55.PubMed Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA: Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol. 1998, 50: 51-55.PubMed
10.
go back to reference Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburge RJ, Mueller BA: Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008, 3: 355-361. 10.2215/CJN.02920707.CrossRefPubMedPubMedCentral Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburge RJ, Mueller BA: Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008, 3: 355-361. 10.2215/CJN.02920707.CrossRefPubMedPubMedCentral
11.
go back to reference Teigen MM, Duffull S, Dang L, Johnson DW: Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol. 2006, 46: 1259-1267. 10.1177/0091270006292987.CrossRefPubMed Teigen MM, Duffull S, Dang L, Johnson DW: Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol. 2006, 46: 1259-1267. 10.1177/0091270006292987.CrossRefPubMed
12.
go back to reference Mac-Kay MV, Fernandez IP, Herrera CJ, Sancez BJ: An in vitro study of the influence of a drug’s molecular weight on its overall (Clt), diffusive (Cld) and convective (Clc) clearance through dialyzers. Biopharm Drug Dispos. 1995, 16: 23-35. 10.1002/bdd.2510160104.CrossRefPubMed Mac-Kay MV, Fernandez IP, Herrera CJ, Sancez BJ: An in vitro study of the influence of a drug’s molecular weight on its overall (Clt), diffusive (Cld) and convective (Clc) clearance through dialyzers. Biopharm Drug Dispos. 1995, 16: 23-35. 10.1002/bdd.2510160104.CrossRefPubMed
13.
go back to reference Pinner NA, Canada RB, Broyles JE, Hudson JQ: Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems. Ren Fail. 2012, 34: 703-707. 10.3109/0886022X.2012.672153.CrossRefPubMed Pinner NA, Canada RB, Broyles JE, Hudson JQ: Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems. Ren Fail. 2012, 34: 703-707. 10.3109/0886022X.2012.672153.CrossRefPubMed
14.
go back to reference Li B, Van Schepdael A, Hoogmartens J, Adams E: Mass spectrometric characterization of gentamicin components separated by the new European Pharmacopoeia method. J Pharm Biomed Anal. 2011, 55: 78-84. 10.1016/j.jpba.2011.01.017.CrossRefPubMed Li B, Van Schepdael A, Hoogmartens J, Adams E: Mass spectrometric characterization of gentamicin components separated by the new European Pharmacopoeia method. J Pharm Biomed Anal. 2011, 55: 78-84. 10.1016/j.jpba.2011.01.017.CrossRefPubMed
15.
go back to reference Atkinson AJ, Umans JG: Pharmacokinetic studies in hemodialysis patients. Clin Pharmacol Ther. 2009, 86: 548-552. 10.1038/clpt.2009.147.CrossRefPubMed Atkinson AJ, Umans JG: Pharmacokinetic studies in hemodialysis patients. Clin Pharmacol Ther. 2009, 86: 548-552. 10.1038/clpt.2009.147.CrossRefPubMed
16.
go back to reference Vancomycin hydrochloride [package insert]. 2012, Lake Forest (IL): Hospira, Inc Vancomycin hydrochloride [package insert]. 2012, Lake Forest (IL): Hospira, Inc
17.
go back to reference Gentamicin solution [package insert]. 2012, Saint Louis (MO): SIGMA Gentamicin solution [package insert]. 2012, Saint Louis (MO): SIGMA
18.
go back to reference Keller F, Wilms H, Schultze F, Offerman G, Molzahn M: Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol. 1983, 19: 201-205.PubMed Keller F, Wilms H, Schultze F, Offerman G, Molzahn M: Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol. 1983, 19: 201-205.PubMed
19.
go back to reference Bressolle F: Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet. 1994, 26: 458-471.CrossRef Bressolle F: Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet. 1994, 26: 458-471.CrossRef
20.
go back to reference Hudson JQ, Comstock TJ, Feldman GM: Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant. 2004, 19: 400-405. 10.1093/ndt/gfg550.CrossRefPubMed Hudson JQ, Comstock TJ, Feldman GM: Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant. 2004, 19: 400-405. 10.1093/ndt/gfg550.CrossRefPubMed
21.
go back to reference Manley HJ, Grabe DW: Determination of iron sucrose (venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in-vitro study. BMC Nephrol. 2004, 5: 1-10.1186/1471-2369-5-1.CrossRefPubMedPubMedCentral Manley HJ, Grabe DW: Determination of iron sucrose (venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in-vitro study. BMC Nephrol. 2004, 5: 1-10.1186/1471-2369-5-1.CrossRefPubMedPubMedCentral
22.
go back to reference Hatton RC, Portales IT, Finlay A, Ross EA: Removal of iron dextran by hemodialysis: an in vitro study. Am J Kidney Dis. 1995, 26: 327-330. 10.1016/0272-6386(95)90653-3.CrossRefPubMed Hatton RC, Portales IT, Finlay A, Ross EA: Removal of iron dextran by hemodialysis: an in vitro study. Am J Kidney Dis. 1995, 26: 327-330. 10.1016/0272-6386(95)90653-3.CrossRefPubMed
Metadata
Title
Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system
Authors
Soo Min Jang
Katie E Cardone
Thomas D Nolin
Darius L Mason
Darren W Grabe
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-204

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.